Cerevance Raises M

Cerevance, a Cambridge, MA-based neuroscience company, raised $21.5m in Series A financing. Founding backers included Takeda Pharmaceutical Company Limited (TOKYO:4502) and Lightstone Ventures, each joining Cerevance’s Board of Directors. The company, which is funded with $36m in total funding, will use the capital to advance a pipeline of therapeutics into the clinic in parallel with scaling up a novel approach to brain diseases based on its new technology. Led by Brad Margus, Chief Executive Officer, Cerevance is a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders by using a new technology created in the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, Ph.D. at the Rockefeller University.Takeda will provide a 25-person neuroscience research team from its Cambridge, United Kingdom site, including industry veteran Mark…

Link to Full Article: Cerevance Raises M

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!